These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12068026)

  • 1. Natural history and treatment of renal involvement in Fabry disease.
    Branton M; Schiffmann R; Kopp JB
    J Am Soc Nephrol; 2002 Jun; 13 Suppl 2():S139-43. PubMed ID: 12068026
    [No Abstract]   [Full Text] [Related]  

  • 2. Alpha-galactosidase activity should be examined in patients with proteinuria: what have we learned from a family affected with Fabry disease?
    Lee NC; Niu DM; Lin CY; Hsiao KJ; Yang AH; Ng YY
    Nephrol Dial Transplant; 2006 Feb; 21(2):549-50. PubMed ID: 16221700
    [No Abstract]   [Full Text] [Related]  

  • 3. New mutation in female patient with renal variant of Fabry disease and HIV.
    Solis MA; Pascual B; Boscá M; Ramos V; Carda C; Monteagudo C; Torregrosa I; Pons S; Miguel A
    J Nephrol; 2010; 23(2):231-3. PubMed ID: 20155722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fabry disease].
    Jakubowska E; Ryba M; Hruby Z
    Przegl Lek; 2006; 63(4):218-9. PubMed ID: 17080745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remarkable variability in renal disease in a large Slovenian family with Fabry disease.
    Verovnik F; Benko D; Vujkovac B; Linthorst GE
    Eur J Hum Genet; 2004 Aug; 12(8):678-81. PubMed ID: 15162124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interdisciplinary approach towards female patients with Fabry disease.
    Weidemann F; Niemann M; Sommer C; Beer M; Breunig F; Wanner C
    Eur J Clin Invest; 2012 Apr; 42(4):455-62. PubMed ID: 22049975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal pathology in Fabry disease.
    Alroy J; Sabnis S; Kopp JB
    J Am Soc Nephrol; 2002 Jun; 13 Suppl 2():S134-8. PubMed ID: 12068025
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of recombinant alpha-galactosidase A therapy for amelioration of the cardiovascular manifestations of Fabry disease: an important role for endomyocardial biopsy.
    Buja LM
    Circulation; 2009 May; 119(19):2539-41. PubMed ID: 19451361
    [No Abstract]   [Full Text] [Related]  

  • 9. [Current management of Fabry disease].
    Cochat P; Liutkus A; Dubourg L; Levade T
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S167-71. PubMed ID: 17373218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapies for Fabry's disease.
    Gahl WA
    N Engl J Med; 2001 Jul; 345(1):55-7. PubMed ID: 11439950
    [No Abstract]   [Full Text] [Related]  

  • 11. Kidney involvement in Anderson-Fabry disease.
    Meroni M; Sessa A; Battini G; Tazzari S; Torri Tarelli L
    Contrib Nephrol; 1997; 122():178-84. PubMed ID: 9399062
    [No Abstract]   [Full Text] [Related]  

  • 12. [Fabry disease--diagnostic guideline].
    Constantin T; Rákóczi E; Ponyi A; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Csikós M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G;
    Orv Hetil; 2010 Feb; 151(7):243-9. PubMed ID: 20133243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations].
    Germain DP
    J Soc Biol; 2002; 196(2):183-90. PubMed ID: 12360747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
    Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
    Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fabry nephropathy and the case for adjunctive renal therapy.
    Wanner C; Breunig F
    J Am Soc Nephrol; 2007 Sep; 18(9):2426-8. PubMed ID: 17699807
    [No Abstract]   [Full Text] [Related]  

  • 16. The Fabry cardiomyopathy: models for the cardiologist.
    Weidemann F; Niemann M; Warnock DG; Ertl G; Wanner C
    Annu Rev Med; 2011; 62():59-67. PubMed ID: 21090963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fabry disease (alpha-galactosidase A deficiency): renal involvement and enzyme replacement therapy.
    Desnick RJ; Wasserstein MP; Banikazemi M
    Contrib Nephrol; 2001; (136):174-92. PubMed ID: 11688379
    [No Abstract]   [Full Text] [Related]  

  • 18. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
    Desnick RJ; Banikazemi M
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fabry disease - complex clinical picture, simple diagnosis procedure, causal treatment].
    Hoffmann B; Beck M; Rolfs A; Neumann HP
    Dtsch Med Wochenschr; 2008 Sep; 133(39):1965-72; quiz 1973-4. PubMed ID: 18798134
    [No Abstract]   [Full Text] [Related]  

  • 20. [Biochemical and pathological studies on a carrier of Fabry's disease manifesting bouts of pain in the extremities].
    Katayama M; Kobayashi T; Ohnishi A; Goto I; Kuroiwa Y
    Rinsho Shinkeigaku; 1984 Jun; 24(6):575-80. PubMed ID: 6094070
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.